VT-464

VT-464 is a nonsteroidal antiandrogen (NSAA) which is under development by Innocrin Pharmaceuticals for the treatment of prostate cancer. It is a CYP17A1 inhibitor and by extension a steroidogenesis inhibitor that is structurally related to the approved medication abiraterone acetate, but that, unlike abiraterone acetate, does not increase mineralocorticoid production.

Pharmacology

VT-464 is a lyase-selective CYP17A1 inhibitor, meaning that it selectively inhibits the lyase activity of CYP17A1. This is in contrast to non-selective CYP17A1 inhibitors like abiraterone acetate, which inhibit both the hydroxylase and lyase activities of CYP17A1. As a result of its selectivity for inhibition of CYP17A1 lyase, VT-464 does not increase mineralocorticoid production, and hence, does not require concomitant administration of a glucocorticoid like prednisone to prevent mineralocorticoid excess syndrome.

Clinical trials

As of 2016, VT-464 is in phase II clinical trials for prostate cancer. Preliminary results have been promising, with a high rate of biochemical response and a favorable safety profile.

See also

• List of investigational antiandrogens

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian